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Aims. Compare physical activity (PA) levels in adults with and without type 1 diabetes and 
identify diabetes-specific barriers to PA.  
Methods. Forty-four individuals with type 1 diabetes and 77 non-diabetic controls in the 
Coronary Artery Calcification in Type 1 Diabetes study wore an accelerometer for 2 weeks. 
Moderate-to-vigorous physical activity (MVPA) was compared by diabetes status using 
multiple linear regression. The Barriers to Physical Activity in Type 1 Diabetes questionnaire 
measured diabetes-specific barriers to PA, and the Clarke hypoglycemia awareness 
questionnaire measured hypoglycemia frequency.  
Results. Individuals with type 1 diabetes engaged in less MVPA, fewer bouts of MVPA, and 
spent less time in MVPA bouts per week than individuals without diabetes (all p<0.05), 
despite no difference in self-reported PA (p>0.05). The most common diabetes-specific 
barrier to PA was risk of hypoglycemia. Individuals with diabetes reporting barriers spent 
less time in MVPA bouts per week than those not reporting barriers (p=0.047).  
Conclusions. Individuals with type 1 diabetes engage in less MVPA than those without 
diabetes despite similar self-reported levels, with the main barrier being perceived risk of 
hypoglycemia. Adults with type 1 diabetes require guidance to meet current PA guidelines 
and reduce cardiovascular risk. 
Keywords: type 1 diabetes, physical activity, accelerometer 
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1. Introduction  
Cardiovascular disease (CVD) is the leading cause of death in individuals with type 1 
diabetes, is a common complication of type 1 diabetes, and presents at significantly higher 
rates and earlier in life in individuals with type 1 diabetes than in individuals without 
diabetes.
1,2
 In people under 40 years of age, the CVD mortality rate is 9 times higher in men 
and 40 times higher in women with type 1 diabetes as compared to men and women without 
diabetes,
3
 and CVD prevalence continues to rise.
4
 Glycemic dysregulation is associated with 
increases in CVD risk and weight gain, both of which have become more prevalent in 
individuals with type 1 diabetes along with obesity; 
5–7
 thus, glycemic and weight control are 
important to prevent future cardiovascular and microvascular complications and to improve 
overall health in individuals with type 1 diabetes.
1,8
  
The American Heart Association and the American Diabetes Association both recommend 
physical activity (PA) for optimizing blood glucose control in individuals with type 1 
diabetes.
9,10
 PA is known to reduce risk of CVD and to aid in the management of diabetes 
complications, 
9
 and higher levels of PA are associated with better glycemic control, lower 
levels of obesity, and a decrease in cardiovascular risk factors in individuals with type 1 
diabetes.
11,12
  
Previous studies have identified barriers to PA that are specific to diabetes and prevent 
individuals with diabetes from engaging in consistent PA,
13
 suggesting that PA may be lower 
in this population due to unique barriers. Additionally, studies have shown that self-reported 
PA levels often differ from objective measures of PA.
14–16
 The primary aim of this study was 
to compare planned leisure-time PA levels in adults with and without type 1 diabetes using 
objective data measured by an accelerometer. In addition, we examined diabetes-specific 
barriers to PA and explored how barriers and hypoglycemic episodes impacted PA in people 
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with type 1 diabetes.  
2. Materials and Methods 
2.1 Study population 
We collected data on PA from 121 adults between the ages of 35 and 76 who initially 
enrolled in the Coronary Artery Calcification in Type 1 Diabetes (CACTI) study between 
March 2000 and May 2002. Participants were followed for 15 years and provided data at 
follow-up study visits occurring between May 2014 and June 2016. A total of 44 adults with 
type 1 diabetes and 77 adults without diabetes agreed to wear an accelerometer to collect PA 
data for a period of two weeks at the follow-up visit and were included in these analyses. All 
participants provided informed consent at baseline and follow-up visits, and all protocols 
were reviewed and approved by the Colorado Multiple Institute Review Board.  
2.2 Physical activity 
Study participants wore an Actigraph wGT3X-BT triaxial accelerometer on the hip for the 
two-week period (mean wear time 14.4 ± 3.6 days). The accelerometer was worn at all times 
except during water activities. Activity counts, calculated as a function of the frequency and 
intensity of acceleration on the X, Y, and Z axes,
17
 were collected at 1-minute intervals. 
Participants additionally logged their PA for the full two-week period and completed a 
validated questionnaire
18
 capturing self-reported sports and leisure PA. Participants reported 
approximate weekly and yearly occupational and leisure periods of PA, and we calculated 
level of activity based on energy expenditure algorithms specific to each activity.
19
  
Wear time validation was conducted in ActiLife version 6.13 to remove periods of non-wear 
from further analysis. The algorithm proposed by Choi et al. was chosen to identify periods 
of wear and non-wear time.
20
 Only participants wearing the accelerometer for a total of at 
least 4 days, with at least 1 weekend day, were included in the analysis to ensure 
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representative data were captured. 
Activity levels were defined using Freedson adult definitions for sedentary, light, moderate, 
vigorous, and very vigorous activity based on the activity counts per minute.
21
 Sedentary 
activity was defined as 0-99 counts per minute; light activity as 100-1951 counts per minute; 
moderate activity as 1952-5724 counts per minute; vigorous activity as 5725-9498; and very 
vigorous activity as greater than 9499 counts per minute. Individuals were considered to be in 
extended bouts of moderate-to-vigorous PA (MVPA) if they engaged in moderate, vigorous, 
or very vigorous activity for at least 10 minutes with a maximum cumulative of 2 minutes of 
rest or inactivity that fell below the MVPA threshold. The bout definitions are intended to 
capture periods of planned activity and are the default in the ActiLife software. They are 
based on current guidelines and research regarding pauses in PA bouts.
21,22
 Bouts of MVPA 
are comparable to the periods of planned PA described by the questionnaire used to capture 
self-reported PA. Non-bout periods of MVPA would include activity meeting the threshold 
for at least moderate activity but lasting fewer than 10 minutes, such as a brisk walk to catch 
a bus.  
The MVPA outcomes assessed in the primary and secondary exploratory analyses were 
average weekly time spent in MVPA, including non-bout periods of MVPA; average weekly 
time spent in bouts of MVPA; and weekly number of MVPA bouts.  
2.3 Barriers to physical activity 
We administered the validated Barriers to Physical Activity in Type 1 Diabetes (BAPAD1) 
questionnaire
13
 to all study participants: participants without diabetes completed a modified 
version of the BAPAD1 with diabetes-specific barriers removed. The questionnaire consists 
of 8 universal barriers to PA relevant to all study participants and 4 diabetes-specific barriers 
(Table 1). Participants were asked how likely each potential barrier is to prevent them from 
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participating in PA using a Likert scale of 1 (extremely unlikely) to 7 (extremely likely). We 
defined individuals as having barriers if they assigned any potential barrier a score of 4 or 
greater. Scores less than 4 were not considered barriers as these were unlikely to prevent 
study participants from engaging in PA.  
2.4 Hypoglycemia frequency 
All study participants with type 1 diabetes completed the Clarke hypoglycemia awareness 
questionnaire
23
 to assess their history of hypoglycemia. Participants self-reported past 
hypoglycemic episodes and the frequency of moderate hypoglycemic episodes in the prior six 
months. Moderate hypoglycemic episodes are those where the participant felt confused, 
disoriented, or lethargic and was unable to treat their hypoglycemia. We designated study 
participants as experiencing infrequent moderate hypoglycemia if they reported fewer than 2 
occurrences in the previous 6 months, and frequent moderate hypoglycemia if they reported 2 
or more occurrences in the previous 6 months.  
2.5 Statistical analysis 
All data analyses were conducted using SAS 9.4 (SAS Institute Inc., Cary, NC). Study 
participants’ demographics, clinical and PA information were compared by diabetes status. 
Mean values and standard deviations of continuous characteristics were obtained and 
compared by diabetes status using two-sided t-tests. Proportions of categorical variables were 
obtained and compared by diabetes status using chi-squared tests for independence.  
The three PA outcomes (average time in MVPA per week, average time in MVPA bouts per 
week, number of MVPA bouts per week) were compared between individuals with and 
without diabetes. We used multiple linear regression to model the mean outcomes for each 
exposure of interest. Because PA levels have been shown to differ between men and women, 
particularly among those with type 2 diabetes,
24,25
 we tested the interaction between sex and 
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the exposure of interest in all models. The final regression models were adjusted for age, sex, 
and accelerometer wear-time. If the interaction p-value between sex and the exposure 
variable was <0.10, this term was included in the model for the purpose of hypothesis 
generating regarding sex differences. For all other analyses, a relationship was considered 
significant at a p-value of 0.05. 
3. Results 
3.1 Physical activity  
Characteristics of study population by diabetes status were compared (Table 2). Participants 
with type 1 diabetes were younger on average and had a more favorable lipid profile than 
participants without diabetes, as previously described.
26
 There was no difference between the 
two groups in sex, BMI, or systolic blood pressure. Self-reported PA did not differ between 
groups: the number of participants reporting universal barriers to PA, the total scores on these 
universal barriers, and the time spent in planned MVPA per week did not differ by diabetes 
status. Based on accelerometer-measured objective PA data, individuals with type 1 diabetes 
spent significantly less time in MVPA bouts per week.  
We compared differences in least-square means for the three MVPA outcomes in both 
participants with and without diabetes (Table 3). After adjustment for age, sex, and 
accelerometer wear-time, individuals with type 1 diabetes spent less time engaging in MVPA 
per week, less time in MVPA bouts per week, and had fewer MVPA bouts total per week 
than individuals without diabetes.  
3.2 Barriers to physical activity 
The frequency with which participants assigned a score of 4 or greater to each diabetes-
specific barrier is presented in Figure 1. The two most common diabetes-specific barriers 
identified were the risk of hypoglycemia, with 11 out of 44 participants (25%) with diabetes 
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identifying it as a barrier (i.e., reporting a Likert score of ≥4), and the fear of loss of control 
over diabetes, with 9 out of 44 participants (21%) identifying it as a barrier.  
Characteristics of study participants with type 1 diabetes stratified by whether or not they 
identified at least one diabetes-specific barrier to PA were compared (Table A.1 in the 
appendix). Participants reporting barriers were younger than those not reporting barriers. 
Participants had similar clinical characteristics and self-reported weekly time spent in 
planned MVPA, regardless of whether they reported diabetes-specific barriers. However, 
participants who reported barriers spent significantly less time engaging in objectively 
measured MVPA per week and engaged in fewer bouts of MVPA per week with less time 
spent in each bout than those who did not report barriers.  
To examine whether reporting diabetes-specific barriers was associated with the low levels of 
PA in participants with type 1 diabetes, we present results for the linear regression analysis of 
PA outcomes in Table 4. Participants reporting barriers spent significantly less time in 
MVPA bouts per week and engaged in significantly fewer bouts of MVPA per week than 
participants who did not report barriers after adjusting for age, sex, and accelerometer wear-
time. There was not a statistically significant difference between groups in average time spent 
in MVPA per week. Diabetes-specific barriers to PA were associated with less MVPA across 
all outcomes, while reporting major universal or no barriers to PA was associated with higher 
levels of MVPA.  
3.3 Hypoglycemia frequency 
Given that the risk of hypoglycemia was the most common barrier to PA in participants with 
type 1 diabetes, we further investigated whether there was a difference in PA by how often 
participants reported having experienced hypoglycemia on the Clarke hypoglycemia 
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questionnaire. Specifically, we aimed to explore whether awareness of frequent 
hypoglycemic episodes in the prior 6 months was associated with the lower PA levels in 
participants with type 1 diabetes. There were significant interactions between sex and 
multiple measures of PA when examining hypoglycemia frequency, and so all results are 
presented further stratified by sex.  
Characteristics of study participants who reported frequent versus infrequent moderate 
hypoglycemic episodes by sex are shown in Table A.2. Within the sample of adults with type 
1 diabetes, 21 participants (14 women) reported frequent hypoglycemic episodes in the 
previous 6 months, and 23 (11 women) reported infrequent hypoglycemic episodes in the 
previous 6 months. There were no significant differences by sex in age or diabetes duration 
within the hypoglycemia frequency groups. There were no significant differences in HbA1c, 
lipid levels, and blood pressure measures. In addition, there were no significant differences in 
either self-reported PA, but there was a significant difference in objectively measured total 
MVPA per week between men and women who reported infrequent hypoglycemia.  
Finally, regression models for each PA outcome by frequent versus infrequent hypoglycemia 
were examined (Table A.3). There was a significant interaction between sex and average 
time spent in MVPA bouts per week (p=0.03) as well as between sex and number of MVPA 
bouts per week (p=0.08); therefore, results for these outcomes are reported separately for 
women and men. There was no significant difference between individuals who experienced 
frequent hypoglycemia compared to those who experienced infrequent hypoglycemia in the 
overall time spent in MVPA per week. Among women, there was no significant difference by 
hypoglycemia frequency in the average time in MVPA bouts per week and the number of 
MVPA bouts per week. However, men reporting frequent hypoglycemia spent less time in 
MVPA bouts per week and had significantly fewer MVPA bouts per week compared to men 
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who reported infrequent hypoglycemia.  
4. Discussion 
Despite similar self-reported PA levels, participants with type 1 diabetes engaged in less 
MVPA activity as measured objectively by an accelerometer than participants without 
diabetes, suggesting that participants with diabetes may overestimate their PA levels. Earlier 
assessments of the CACTI study cohort also showed no significant differences in self-
reported PA by diabetes status (p=0.79),
27
 but objectively measured PA data were not 
previously collected and could not be compared by diabetes status or to self-reported PA 
levels. Regardless of diabetes status, objective measurements of PA were lower than self-
reported measurement of PA, a discrepancy consistent with other studies that have compared 
self-reported and objective PA,
15,16
 and the difference between objectively measured and self-
reported PA was greater in individuals with type 1 diabetes than in those without diabetes. 
This difference by diabetes status may be driven by unawareness of reduced exercise 
capacity, or due to inaccurate perceptions of greater exercise intensity that have been found in 
individuals with type 2 diabetes.
28
 Our results emphasize that adults with type 1 diabetes 
engage in low levels of actual PA compared to recommended guidelines and to a similar 
group of non-diabetic individuals, despite reporting similar universal barriers to PA. 
Diabetes-specific barriers, primarily the perceived risk of hypoglycemia, appear to show 
strong associations with lower levels of PA in individuals with type 1 diabetes despite higher 
perceived levels of PA.  
Previous research and current medical guidelines have detailed the importance of PA, 
especially MVPA, in reducing the risk of CVD. The Centers for Disease Control and 
Prevention, the American Heart Association, and the American Diabetes Association all 
prescribe a standard of 150 minutes per week of moderate intensity PA in adults to improve 
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cardiovascular health.
9,10,29
 Meeting these guidelines for PA is of even greater importance in 
individuals with type 1 diabetes, who are at increased risk of developing CVD when 
compared to individuals without diabetes. Type 1 diabetes and CVD prevalence both 
continue to increase, and individuals with type 1 diabetes are often diagnosed in childhood or 
adolescence, amplifying their risk of developing CVD.
1
 Increased PA is one way of lowering 
the risk of CVD events in individuals with type 1 diabetes, and, conversely, physical 
inactivity has been shown to predict cardiovascular events even after adjusting for other 
markers of CVD risk (RR 1.26, 95% CI: 1.08, 1.46).
30
  
Previous studies have explored PA levels and the risk of CVD among individuals with type 1 
diabetes. One study found that participation in consistent low-intensity aerobic activity 
resulted in improved endothelial function and capillary density,
31
 stressing the clinical 
importance of PA in individuals with type 1 diabetes. The majority (63%) of 18,028 
participants with type 1 diabetes in the Diabetes-Patienten-Verlaufsdokumentation (DPV) 
registry were inactive and only 17.8% of the participants engaged in PA more than twice a 
week, highlighting the need to increase levels of PA in this population.
12
 In comparison, 
CACTI participants with diabetes engaged in bouts of PA 3 times a week on average, but still 
significantly less than participants without diabetes. A study of participants in the Type One 
Diabetes Exchange Registry found that a higher BMI and longer duration of type 1 diabetes 
were both associated with increased odds of no PA.
32
 This study suggested that individuals 
concerned about blood glucose levels may engage in less PA as frequent checking of blood 
glucose levels was associated with lower odds of PA, suggesting that individuals who are 
concerned about blood glucose levels may engage in less PA. Awareness of previous 
hypoglycemic episodes has the potential to influence the decision to engage in PA, and our 
results did show an association between frequent hypoglycemic episodes and planned bouts 
of MVPA that differed by sex, where the relationship was only significant among men. 
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Participants who experienced frequent hypoglycemia in the CACTI sample also tended to 
spend less overall time in MVPA per week; however, differences were not statistically 
significant, perhaps due to the small sample size (n=44).  
Finally, studies exploring barriers to PA in children and adults with type 1 diabetes have 
identified the risk of hypoglycemia
13,33,34
 and the risk of hyperglycemia
34,35
 as targets that 
must be addressed when creating effective exercise guidelines for this population. PA may 
result in hyperglycemia during exercise or in delayed hypoglycemia, and previous episodes 
of hypoglycemia are associated with future episodes of hypoglycemia.
36
 A 2017 review 
summarized the benefits of PA in type 1 diabetes management and the importance of 
considering glycemic imbalance when publishing exercise guidelines. While the risk of 
delayed onset hypoglycemia can be mitigated by reduced insulin doses or increased 
carbohydrate consumption before aerobic PA, all PA requires constant monitoring of blood 
glucose levels to ensure hypoglycemia does not occur.
37
 In our sample, the most common 
barrier to PA likely preventing an individual from exercising was the risk of hypoglycemia. 
Diabetes-specific barriers to PA were associated with spending less time in and engaging in 
fewer MVPA bouts per week among individuals with diabetes, indicating that addressing 
potential barriers, particularly the perceived risk of hypoglycemia, might improve PA rates in 
populations with type 1 diabetes.  
The current study has inherent strengths and limitations. One major limitation of these 
analyses is the small sample size of CACTI participants who had accelerometer data; 
however, the results of these analyses inform the development of studies with increased 
power in the future. Additionally, it is possible that PA was not accurately captured by the 
accelerometer. We addressed this limitation by using a validated algorithm for identifying 
periods of wear and non-wear with the understanding that activity done during periods of 
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non-wear (e.g., water activities) were not captured and were only recorded via self-report. To 
ensure that these periods of non-wear were not driving the results we saw, we recalculated 
self-reported PA without water activities and found that these activities did not account for 
the discrepancy between objective and self-reported PA. Although we supplemented the 
objective PA data with self-reported data from a number of validated questionnaires, 
interpretation of the self-reported data alongside the objective data should be done with 
caution due to the various time periods being considered by each measurement tool. For 
example, the hypoglycemia awareness questionnaire refers to hypoglycemic episodes that 
occurred in the previous six months which may not be directly comparable to the two weeks 
that the accelerometer was worn. Furthermore, we did not measure fear of hypoglycemia, 
which differs from measurement of perceived risk of hypoglycemia as a barrier to PA that we 
did measure using the BAPAD1. Finally, these analyses were cross-sectional in nature and a 
potential observer effect may have caused study participants who agreed to wear the 
accelerometer to engage in more PA than usual. These results cannot be extrapolated to PA at 
previous visits. Nevertheless, the longitudinal CACTI study has collected self-report PA data 
on individuals with and without type 1 diabetes for more than 15 years which can be 
examined over time for temporal trends, although likely not an accurate representation of 
actual PA.  
5. Conclusions 
Addressing the perceived risk of hypoglycemia associated with PA and the other diabetes-
specific barriers – having diabetes, loss of control over diabetes, and the risk of 
hyperglycemia – is imperative for improving cardiovascular health in this population, as 
actual PA levels are lower than they may be perceived. PA recommendations should be 
developed for balancing glycemic control with PA and to align with current guidelines.
34,35
 
To meet current guidelines, individuals with type 1 diabetes may require additional support 
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and guidance to objectively measure their PA levels, engage in PA safely, and increase 
overall PA.  
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8. Tables and Figures 
Table 1. Universal and diabetes-specific barriers measured by the BAPAD1. 
Universal barriers Diabetes-specific barriers 
Fear of being tired Loss of control over diabetes 
Fear of hurting self Risk of hypoglycemia 
Fear of suffering a heart attack Fact that you have diabetes 
Low fitness level Risk of hyperglycemia 
Actual physical health status (excluding diabetes) 
 Weather conditions 
 Location of a gym 
 Work schedule 
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Table 2. Study population characteristics by diabetes status. 
Participant characteristic 
Type 1 
diabetes 
(n=44) 
Non-
diabetic 
(n=77) 
p-value 
Demographics 
Age (mean years ± SD) 49 ± 9 56 ± 8 <0.0001 
Female sex (n [%]) 25 [56.8] 40 [52.0] 0.61 
Duration of diabetes (mean years ± SD) 36 ± 8 -- -- 
Use of insulin pump (vs. insulin injection, n [%])  17 [38.6] -- -- 
CGM use (n, [%]) 33 [75.0]   
Clinical information 
HbA1c (mean % ± SD [mean mmol/mol ± SD]) 
7.7 ± 1.4 
 [61 ± 15.2] 
5.6 ± 0.6  
[38 ± 6.2] 
<0.0001 
Total cholesterol (mean mg/dL ± SD) 159 ± 37 176 ± 33 0.01 
HDL-cholesterol (mean mg/dL ± SD) 58 ± 14 52 ± 14 0.02 
LDL-cholesterol (mean mg/dL ± SD) 89 ± 31 106 ± 27 0.002 
Triglycerides (mean mg/dL ± SD) 62 ± 20 92 ± 53 <0.0001 
BMI (mean kg/m
2
 ± SD) 26.9 ± 4.8 27.1 ± 5.1 0.80 
Systolic blood pressure (mean mmHg ± SD) 118 ± 10 120 ± 16 0.29 
Diastolic blood pressure (mean mmHg ± SD) 72 ± 8 76 ± 10 0.04 
Self-reported PA information 
Time in planned MVPA per week (mean min ± SD) 274 ± 188  261 ± 360 0.83 
Universal barriers to PA with score ≥ 4 (n [%]) 24 [54.6] 41 [53.3] 0.89 
Score on universal barriers to PA (mean score ± SD) 16 ± 7 15 ± 7 0.46 
Diabetes-specific barriers to PA with score ≥ 4 (n [%]) 15 [34.1] -- -- 
Score on diabetes-specific barriers to PA (mean score ± SD) 7 ± 4 -- -- 
Measured PA information 
Total time in MVPA per week (mean min ± SD) 209 ± 180 335 ± 224 0.002 
Number of MVPA bouts per week (mean number ± SD) 3 ± 4 5 ± 6 0.01 
Time in MVPA bouts per week (mean min ± SD) 37 ± 64 70 ± 100 0.03 
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Table 3. Least square means and 95% CIs for linear regression models of PA outcomes 
by diabetes status, adjusted for age, sex, and accelerometer wear-time.  
Outcome of interest 
Type 1 diabetes 
(n=44) 
Non-diabetic 
(n=77) 
p-value 
Average time in 
MVPA per week 
(min.) 
201.0 (136.1, 265.8) 344.3 (296.4, 392.2) 0.0009 
Average time in 
MVPA bouts per week 
(min.)  
33.6 (6.4, 60.8) 73.5 (53.4, 93.7) 0.03 
Number of MVPA 
bouts per week (min.)  
2.4 (0.9, 3.9) 5.1 (4.0, 6.3) 0.008 
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Figure 1. Number of participants with type 1 diabetes who reported diabetes-specific 
barriers to PA.  
 
*Total number of participants with diabetes = 44 
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Table 4. Least square means and 95% CIs of linear regression models of PA outcomes 
for type 1 diabetic participants by reporting of diabetes-specific barriers, adjusted for 
age, sex, and accelerometer wear-time.  
 
Outcome of interest 
One or more barriers with 
score ≥ 4 
(n=15) 
No barriers with score ≥ 4 
(n=29) 
p-value 
Average time in 
MVPA per week 
(min.) 
142.2 (48.6, 235.7) 257.8 (192.5, 323.1) 0.06 
Average time in 
MVPA bouts per week 
(min.)  
12.5 (-19.9, 44.9) 54.4 (31.8, 77.0) 0.047 
Number of MVPA 
bouts per week (min.)  
0.6 (-1.2, 2.4) 4.0 (2.7, 5.2) 0.005 
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APPENDIX A. Additional tables for exploratory analyses 
Table A.1. Characteristics of study participants with type 1 diabetes by report of 
diabetes-specific barriers to PA.  
 
Barriers with 
score ≥ 4 
(n=15) 
No barriers 
with score ≥ 4 
(n=29) 
p-value 
Demographics 
Age (mean years ± SD) 43 ± 4 52 ± 10 0.0001 
Female sex (n [%]) 8 [53.3] 17 [58.6] 0.74 
Duration of diabetes (mean years ± SD) 33 ± 6 37 ± 9 0.13 
Use of insulin pump (vs. insulin injection, n [%])  4 [26.7] 13 [44.8] 0.24 
CGM use (n [%]) 14 [93.3] 19 [65.5] 0.04 
Clinical information 
HbA1c (mean % ± SD [mean mmol/mol ± SD]) 
7.3 ± 0.8 
[57 ± 9.2] 
8.0 ± 1.5 
[63 ± 16.7] 
0.09 
Total cholesterol (mean mg/dL ± SD) 157 ± 49 161 ± 29 0.78 
HDL-cholesterol (mean mg/dL ± SD) 52 ± 14 62 ± 13 0.03 
LDL-cholesterol (mean mg/dL ± SD) 92 ± 42 87 ± 24 0.63 
Triglycerides (mean mg/dL ± SD) 62 ± 24 62 ± 18 0.99 
BMI (mean kg/m
2
 ± SD) 27.9 ± 4.4 26.4 ± 5.0 0.34 
Systolic blood pressure (mean mmHg ± SD) 120 ± 12 116 ± 10 0.28 
Diastolic blood pressure (mean mmHg ± SD) 76 ± 8 70 ± 6 0.02 
Self-reported PA information 
Time in planned MVPA per week (mean min ± SD) 364 ± 393 229 ± 198 0.24 
Universal barriers to PA with score ≥ 4 (n [%]) 11 [73.3] 13 [44.8] 0.07 
Score on universal barriers to PA (mean score ± SD) 20 ± 8  14 ± 6  0.27 
Score on diabetes-specific barriers to PA (mean score ± SD) 12 ± 5 5 ± 2 0.001 
Measured PA information 
Total time in MVPA per week (mean min ± SD) 137 ±73 245 ± 208 0.02 
Number of MVPA bouts per week (mean number ± SD) 1 ±1 3 ± 4 0.01 
Time in MVPA bouts per week (mean min ± SD) 18 ±27 47 ± 75 0.07 
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Table A.2. Characteristics of participants with type 1 diabetes by frequency of moderate 
hypoglycemic episodes. 
 
Frequent 
hypoglycemia 
Infrequent 
hypoglycemia 
 
Men 
(n=9) 
Women 
(n=14) 
Men 
(n=10) 
Women 
(n=11) 
Demographics     
Age (mean years ± SD) 46 ± 9 53 ± 8 51 ± 10 45 ± 7 
Duration of diabetes (mean years ± SD) 35 ± 6 37 ± 10 38 ± 10 33 ± 4 
Use of insulin pump (vs. insulin injection, n [%])  2 [22.2] 7 [50.0] 4 [40.0] 4 [36.4] 
CGM use (n, [%]) 7 [77.8] 9 [64.3] 8 [80.0] 9 [81.8] 
Clinical information     
HbA1c (mean % ± SD [mean mmol/mol ± SD]) 
7.9 ± 2.1 
[63 ± 23] 
7.9 ± 1.2 
[63 ± 13.1]  
7.4 ± 0.7 
[57 ± 7.7] 
7.7 ± 1.3 
[61 ± 14.2] 
Total cholesterol (mean mg/dL ± SD)
†
 172 ± 36 169 ± 35 153 ± 47 142 ± 22 
HDL-cholesterol (mean mg/dL ± SD) 59 ± 18 63 ± 13 49 ± 10 60 ± 14 
LDL-cholesterol (mean mg/dL ± SD) 101 ± 26 94 ± 33 89 ± 42 71 ± 12 
Triglycerides (mean mg/dL ± SD) 62 ± 26 59 ± 11 73 ± 23 57 ± 19 
BMI (mean kg/m
2
 ± SD) 25.5 ± 3.0 28.5 ± 5.5 27.2 ± 3.3 25.8 ± 6.0 
Systolic blood pressure (mean mmHg ± SD) 114 ± 16 120 ± 10 122 ± 8 116 ± 8 
Diastolic blood pressure (mean mmHg ± SD) 76 ± 12 68 ± 4 74 ± 4 72 ± 6 
Self-reported PA information     
Time in planned MVPA per week (mean min ± SD) 447 ± 462 268 ± 197 134 ± 111 267 ± 255 
Universal barriers to PA with score ≥ 4 (n [%]) 6 [66.7] 7 [50.0] 4 [40.0] 7 [63.6] 
Score on universal barriers to PA (mean score ± SD) 17 ± 5 15 ± 6 13 ± 5 19 ± 10 
Diabetes-specific barriers to PA with score ≥ 4 (n [%]) 4 [44.4] 2 [14.3] 3 [30.0] 6 [54.6] 
Score on diabetes-specific barriers to PA (mean score 
± SD) 
8 ± 4 6 ± 2 6 ± 3 10 ± 7 
Measured PA information     
Total time in MVPA per week (mean min ± SD)
*
 259 ± 289 138 ± 112 312 ± 168 163 ± 95 
Number of MVPA bouts per week (mean number ± 
SD) 
1.9 ± 1.7 1.7 ± 2.1 5.5 ± 6.4 1.8 ± 2.0 
Time in MVPA bouts per week (mean min ± SD) 12 ± 9 23 ± 29 94 ± 113 25 ± 29 
*
Participant characteristics that differ significantly by sex (p<0.05) 
†
Participant characteristics that differ significantly by hypoglycemia frequency (p<0.05) 
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Table A.3. Least square means and 95% CIs of linear regression models of PA outcomes 
by frequency of hypoglycemia among participants with type 1 diabetes, adjusted for 
age, sex, and accelerometer wear-time.  
 
Outcome of interest 
Frequent hypoglycemia 
(n=21) 
Infrequent hypoglycemia 
(n=23) 
p-value 
Average time in 
MVPA per week 
(min.)  
196.1 (123.7, 268.5) 241.6 (166.7, 316.5) 0.38 
Average time in 
MVPA bouts per week 
(min.)  
  0.03 
Women 26.1 (-6.8, 58.9) 21.5 (-15.5, 58.5) 0.86 
Men 9.3 (-30.7, 49.3) 95.2 (57.5, 132.9) 0.003 
Number of MVPA 
bouts per week (min.) 
  0.08 
Women 1.9 (-0.1, 3.8) 1.6 (-0.7, 3.8) 0.83 
Men 1.8 (-0.6, 4.2) 5.6 (3.4, 7.9) 0.02 
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